Evotec SE announced today that the Company has reached another programme designation within its neuroscience collaboration with Bristol Myers Squibb triggering a payment of US$ 16 m to Evotec. The programme further adds to a fast-growing pipeline in neurodegeneration that also includes EVT8683, which entered clinical development end of 2021. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-programme-designation-in-neuroscience-collaboration-with-bristol-myers-squibb-6161